Membranous nephropathy (MN) is characterized histomorphologically by the presence of
immune deposits in the subepithelial space of the glomerular filtration barrier; its clinical …

Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. In adults,
it is the most frequent cause of nephrotic syndrome. In~ 80% of patients, there is no …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for
membranous nephropathy. Compared with this regimen, rituximab therapy might have a …

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a
Controversies Conference on glomerular diseases in November 2017. The conference …

The discovery in 2009 of the M-type phospholipase A2 receptor (PLA2R) as the primary
target in membranous nephropathy (MN) greatly advanced basic and clinical research …

Results Remissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX
cohort (P= 0.02) at month 6, respectively, and in 24 (86%) versus 18 (67%) participants (P …

Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies
against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin …

The phospholipase A2 receptor 1 (PLA2R1) is the major autoantigen in patients suffering
from membranous nephropathy. To date, the lack of endogenous glomerular expression of …

Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-
antibodies targeting podocyte antigens resulting in activation of complement and damage to …